Calyxt, Inc. (NASDAQ:CLXT) has received a consensus broker rating score of 1.67 (Buy) from the three brokers that provide coverage for the company, Zacks Investment Research reports. One research analyst has rated the stock with a hold rating and two have assigned a strong buy rating to the company.
Brokerages have set a 12 month consensus price objective of $20.67 for the company, according to Zacks. Zacks has also given Calyxt an industry rank of 185 out of 265 based on the ratings given to related companies.
Several research firms recently commented on CLXT. Wells Fargo & Company upped their price target on shares of Calyxt from $17.00 to $30.00 and gave the company an “outperform” rating in a research note on Friday, September 29th. Jefferies Group LLC began coverage on shares of Calyxt in a research note on Monday, August 14th. They issued a “buy” rating and a $16.00 price target on the stock. Finally, Citigroup Inc. downgraded shares of Calyxt from a “buy” rating to a “neutral” rating in a research note on Wednesday, September 27th.
Shares of Calyxt (NASDAQ CLXT) traded down 0.19% during mid-day trading on Thursday, hitting $26.44. 45,356 shares of the stock traded hands. The company’s 50 day moving average is $21.78 and its 200 day moving average is $18.52. The firm’s market capitalization is $518.22 million. Calyxt has a one year low of $9.26 and a one year high of $29.45.
TRADEMARK VIOLATION WARNING: This report was first reported by BBNS and is owned by of BBNS. If you are accessing this report on another domain, it was stolen and reposted in violation of U.S. & international copyright legislation. The legal version of this report can be read at https://baseballnewssource.com/markets/calyxt-inc-clxt-given-20-67-average-price-target-by-analysts/1699871.html.
Calyxt Company Profile
Calyxt, Inc is a food and agriculture company. The Company is focused on delivering healthier specialty food ingredients, such as healthier oils and high fiber wheat, for consumers and agriculturally advantageous crop traits, such as herbicide tolerance to farmers. The Company also combines gene-editing technology and technical that enables to edit a plant genome to elicit the desired traits and characteristics.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Calyxt Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Calyxt Inc. and related companies with our FREE daily email newsletter.